Medpace Holdings, Inc. $MEDP Shares Bought by Strategic Global Advisors LLC

Strategic Global Advisors LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 192.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 11,031 shares of the company’s stock after buying an additional 7,257 shares during the quarter. Strategic Global Advisors LLC’s holdings in Medpace were worth $6,196,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. AQR Capital Management LLC increased its stake in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the last quarter. Franklin Resources Inc. increased its stake in Medpace by 158.6% during the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after acquiring an additional 183,645 shares during the last quarter. Norges Bank acquired a new stake in Medpace during the fourth quarter worth $102,156,000. Finally, Goldman Sachs Group Inc. increased its stake in Medpace by 92.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after acquiring an additional 166,654 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on MEDP shares. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and cut their target price for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Robert W. Baird lowered their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Barclays lowered their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Finally, Royal Bank Of Canada lowered their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $467.08.

Medpace Price Performance

MEDP opened at $467.34 on Monday. Medpace Holdings, Inc. has a 52 week low of $294.07 and a 52 week high of $628.92. The business has a fifty day simple moving average of $456.43 and a 200-day simple moving average of $503.84. The firm has a market cap of $13.35 billion, a P/E ratio of 29.37, a P/E/G ratio of 2.37 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period last year, the business posted $3.67 earnings per share. The company’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.